SGLT2 Inhibitors

Originally developed for Type 2 Diabetes, drugs like Canagliflozin have shown surprising cardiovascular and renal protective benefits in non-diabetics, alongside ITP data showing lifespan extension in mice. Off-label use for longevity is increasing rapidly.